-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
MIMEDX Appoints Matt Notarianni as Head of Investor Relations
MIMEDX Appoints Matt Notarianni as Head of Investor Relations
Experienced Healthcare-focused Financial and Communications Leader to Strengthen and Expand Relationships with Investment Community
MARIETTA, Ga., Oct. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced the appointment of Matt Notarianni as Head of Investor Relations (IR), effective immediately. Mr. Notarianni joins MIMEDX with over 15 years of healthcare-focused Wall Street and IR experience, most recently serving as head of IR for Cerus Corporation.
"I am delighted to welcome Matt to MIMEDX," stated K. Todd Newton, MIMEDX interim Chief Executive Officer. "The breadth of Matt's experience in healthcare-focused financial services, IR and strategy roles make him a great fit to amplify the MIMEDX story to the investment community. I look forward to working with Matt to continue to evolve our IR strategy and heighten our engagement level with current and prospective investors and analysts."
"I am thrilled to join MIMEDX at this critical time at the Company," Mr. Notarianni stated. "As a pioneer and the leader in placental biologics, MIMEDX has a strong business with a number of compelling growth opportunities ahead. I look forward to working with the management team and Board to help realize these opportunities and communicate the Company's progress with the investment community."
Jack Howarth, MIMEDX Senior Vice President of Investor Relations, will continue to support the MIMEDX IR function until his planned retirement at the end of this year.
"On behalf of the entire MIMEDX team, I want to thank Jack for his many contributions to the Company over the years," continued Mr. Newton. "With a career spanning over four decades, we wish Jack a wonderful retirement."
Prior to his role at Cerus, Mr. Notarianni was at Immucor, Inc. from 2012-2021, serving most recently as Senior Director, Corporate Development & External Communications. He began his career as an equity research analyst at Robert W. Baird & Co. covering the life science tools and diagnostics space. Mr. Notarianni received his B.S. in Business Administration from Marquette University.
About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit .
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com
Experienced Healthcare-focused Financial and Communications Leader to Strengthen and Expand Relationships with Investment Community
以医疗保健为重点的经验丰富的金融和通信领导,加强和扩大与投资界的关系
MARIETTA, Ga., Oct. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced the appointment of Matt Notarianni as Head of Investor Relations (IR), effective immediately. Mr. Notarianni joins MIMEDX with over 15 years of healthcare-focused Wall Street and IR experience, most recently serving as head of IR for Cerus Corporation.
全球新闻网佐治亚州玛丽埃塔10月4日电变革性胎盘生物制剂公司MiMedx Group,Inc.(纳斯达克代码:MDXG)今天宣布任命Matt Notaanni为投资者关系部主管,即刻生效。诺塔安尼先生加盟MiMedx,拥有15年以上专注于医疗保健的华尔街和投资者关系经验,最近担任的是Cerus公司的投资者关系主管。
"I am delighted to welcome Matt to MIMEDX," stated K. Todd Newton, MIMEDX interim Chief Executive Officer. "The breadth of Matt's experience in healthcare-focused financial services, IR and strategy roles make him a great fit to amplify the MIMEDX story to the investment community. I look forward to working with Matt to continue to evolve our IR strategy and heighten our engagement level with current and prospective investors and analysts."
MiMedx临时首席执行官K·托德·牛顿表示:“我很高兴欢迎马特加入MiMedx。马特在以医疗保健为重点的金融服务、投资者关系和战略角色方面的丰富经验使他非常适合向投资界扩大MiMedx的故事。我期待着与马特合作,继续发展我们的国际关系战略,并提高我们与现有和潜在投资者和分析师的接触水平。“
"I am thrilled to join MIMEDX at this critical time at the Company," Mr. Notarianni stated. "As a pioneer and the leader in placental biologics, MIMEDX has a strong business with a number of compelling growth opportunities ahead. I look forward to working with the management team and Board to help realize these opportunities and communicate the Company's progress with the investment community."
诺塔安尼先生说:“我很高兴能在公司的这一关键时刻加入MiMedx。作为胎盘生物制剂领域的先驱和领导者,MiMedx拥有强大的业务和许多引人注目的增长机会。我期待着与管理团队和董事会合作,帮助实现这些机会,并与投资界沟通公司的进展。
Jack Howarth, MIMEDX Senior Vice President of Investor Relations, will continue to support the MIMEDX IR function until his planned retirement at the end of this year.
投资者关系部MiMedx高级副总裁的Jack Howarth将继续支持MiMedx的投资者关系职能,直到他计划于今年年底退休。
"On behalf of the entire MIMEDX team, I want to thank Jack for his many contributions to the Company over the years," continued Mr. Newton. "With a career spanning over four decades, we wish Jack a wonderful retirement."
牛顿先生继续说道:“我想代表整个MiMedx团队感谢杰克多年来为公司做出的许多贡献。他的职业生涯长达40多年,我们祝愿他退休后生活愉快。
Prior to his role at Cerus, Mr. Notarianni was at Immucor, Inc. from 2012-2021, serving most recently as Senior Director, Corporate Development & External Communications. He began his career as an equity research analyst at Robert W. Baird & Co. covering the life science tools and diagnostics space. Mr. Notarianni received his B.S. in Business Administration from Marquette University.
在加入Cerus之前,Notaanni先生于2012年至2021年在Immoor,Inc.任职,最近担任董事企业发展和对外公关部高级主管。他的职业生涯始于罗伯特·W·贝尔德公司(Robert W.Baird&Co.)的股票研究分析师,负责生命科学工具和诊断领域。诺塔安尼先生拥有马凯特大学工商管理学士学位。
About MIMEDX
关于MiMedx
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit .
MiMedx是一家变革性的胎盘生物制剂公司,开发和分销具有专利保护的同种异体胎盘组织移植,适用于多个医疗保健部门。作为胎盘组织工程的先驱,我们既有专注于满足急慢性不可愈合伤口患者需求的商业业务,也有旨在为退行性肌肉骨骼疾病患者减轻疼痛和改善功能的前景看好的后期管道。我们的产品来自人类胎盘组织,并使用我们的专利方法处理这些组织,包括PURION®进程。我们采用当前良好的组织实践、当前良好的制造规范和终端灭菌来生产我们的同种异体移植物。MiMedx通过直运和寄售两种方式提供了200多万个同种异体移植物。欲了解更多信息,请访问。
Contact:
联系方式:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com
马特·诺塔安尼
投资者关系
470-304-7291
邮箱:mnotaanni@miedx.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧